Tag Archives: pelacarsen

Tirzepatide SUMMIT HFpEF Topline Results; Regeneron, Alnylam, Ionis, Teladoc, Amarin, and Biomea Q2 ’24 Earnings; Antag Increases Series A Funding for GIP Antagonism; Sanofi Expands Insulin Manufacturing in Germany; Boston Pharmaceuticals MASH Updates

A series of cardiometabolic-related news items have been observed from Lilly, Regeneron, Alnylam, Antag Therapeutics, Sanofi, Boston Pharmaceuticals, Ionis, Teladoc, Amarin, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items, including initial thoughts on Lilly’s tirzepatide HFpEF results in the context of Novo’s STEP HFpEF and apparent regulatory delay.

This content is for Read Less members only.
Register
Already a member? Log in here

JPM 2024 Day 3: TRNS, ESPR, IONS, AMRN, EMBC, and VTRS

On the third day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Terns, Esperion, Ionis, Amarin, Embecta, and Viatris. Tomorrow is the final day of the JPM 2024 conference with presentations from Lexicon, Mannkind, and Xeris.

This content is for Read Less members only.
Register
Already a member? Log in here

Novartis 2023 Investor Day Pipeline Updates; New Lilly Obesity Asset

Two cardiometabolic-related news items have been observed: Novartis hosted its 2023 R&D day (press release; webcast; slides); and Lilly initiated a Ph1 SAD/MAD study evaluating a new asset with an unknown MOA (LY3971297) in healthy participants with obesity and hypertension (view CT.gov record). Below, FENIX provides highlights and insights into the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Terns Announces Positive Topline Ph2a NASH Data; Ionis Q2 ’23 Earnings

Two cardiometabolic-related news items have been observed: Terns Pharmaceuticals announced positive topline results from its Ph2a DUET trial evaluating TERN-501 as a monotherapy or in combination with TERN-101 for the treatment of NASH (view CT.gov record; press release); and Ionis hosted its Q2 ’23 earnings call (view press release; slides). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Novartis Hosts 2021 R&D Webinar

Novartis hosted its 2021 R&D webinar (view here; slides) and provided a company-wide outlook through 2030 with regard to its cardio-renal pipeline, management focused on Leqvio (PCSK9i for ASCVD), pelacarsen (Lp(a) for ASCVD), and iptacopan (Factor B Complement for nephrology and hematology). There was only brief commentary regarding Entresto’s continued growth. Below, FENIX provides highlights and insights from the Novartis R&D event.

This content is for Read Less members only.
Register
Already a member? Log in here